Natera May 16, 2022 Natera Files New Patent Infringement Lawsuit Against CareDx May 5, 2022 Natera Q1 Revenues Rise 28 Percent on Increased Product Revenues Apr 29, 2022 In Brief This Week: Mayo Clinic, Quest Diagnostics, Castle Bio, Becton Dickinson, PerkinElmer, More Apr 20, 2022 Natera Adds Clinical Utility Evidence for Cell-Free DNA in Allograft Health Premium Apr 20, 2022 FDA Cautions of False Results From Prenatal Genetic Tests Apr 1, 2022 360Dx Top 30 Falls Slightly in March Mar 16, 2022 Lead Independent Director of Natera Board Invests $5M in Company Mar 15, 2022 Jury Awards CareDx $44.9M in Natera Lawsuit; Finds Both Companies Engaged in False Advertising Mar 9, 2022 Natera Refutes Claims in Short Seller Report After Stock Plummets Mar 9, 2022 Natera Minimal Residual Disease Test Value Called Into Question by City of Hope CRC Patient Data Feb 25, 2022 Natera Hit With Multiple Class Action Suits Over 'Unreliable' NIPT Results Feb 24, 2022 Natera Q4 Revenues Grow 54 Percent Jan 20, 2022 In Ongoing False Advertising Suit, Judge Allows Natera Counterclaims Against Guardant Health Jan 11, 2022 JP Morgan Healthcare Conference Day 1: Qiagen, Adaptive Bio, Guardant Health, Natera, Sema4 Dec 3, 2021 In Brief This Week: Roche, Veracyte, Hologic, Danaher, Chembio Diagnostics, Natera, and More Nov 22, 2021 Invitae Sues Natera Over Alleged Infringement of Sequence Assembly Patents Nov 19, 2021 Natera Accused of Unfair, Deceptive Billing Practices Related to NIPT Services in New Lawsuit Nov 5, 2021 Natera Aiming to Translate Success in Colorectal Cancer Diagnostics Into Other Areas Premium Nov 4, 2021 Natera Q3 Revenues Grow 61 Percent Oct 28, 2021 BGI Genomics Program Seeks to Validate Signatera Test for Colorectal Cancer Patients in China Premium Load More Breaking News BARDA Provides Additional $3.7M to T2 Biosystems Under Contract Option Careviso Closes $17.4M Series B Funding Round P4 Diagnostix, Pierian Partner to Offer Somatic Prostate Cancer Testing MiRxes Launches Study for Pulmonary Hypertension Biomarkers in Asian Populations OraSure Technologies Awarded $8.6M BARDA Contract for Next-Gen Ebola Test BioAffinity Technologies Nabs $15.6M from Public Offering
